Antigenicity and Diagnostic Potential of Vaccine Candidates in Human Chagas Disease

PLoS Neglected Tropical Diseases

Volumn 7, Issue 1, 2013, Pages

  Gupta, Shivali ^a   Wan, Xianxiu ^a   Zago, Maria P ^b   Martinez Sellers, Valena C ^a   Silva, Trevor S ^a   Assiah, Dadjah ^a   Dhiman, Monisha ^a   Nuñez, Sonia ^c   Petersen, John R ^a   Vázquez Chagoyán, Juan C ^d   Estrada Franco, Jose G ^d   Garg, Nisha Jain ^a,e  

^a University of Texas Medical Branch School of Medicine   (United States)

^b Universidad Nacional de Río Cuarto Consejo Nacional de Investigaciones Científicas y Técnicas   (Argentina)

^c Hospital Público de Gestión Descentralizada San Bernardo HPGDSA   (Argentina)

^d UNIVERSIDAD AUTÓNOMA DEL ESTADO DE MÉXICO   (Mexico)

^e UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; IMMUNOGLOBULIN G ANTIBODY; RECOMBINANT ANTIGEN; RECOMBINANT PROTEIN;

ADULT; AGED; ANTIBODY RESPONSE; ANTIGENICITY; ARGENTINA; ARTICLE; CHAGAS DISEASE; CROSS REACTION; DISESE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEXICO; NONHUMAN; NUCLEOTIDE SEQUENCE; SCREENING; SEROLOGY; TRYPANOSOMA CRUZI;

EID: 84873508036     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0002018     Document Type: Article

References (37)

1. Schmunis GA, Yadon ZE, (2010) Chagas disease: a Latin American health problem becoming a world health problem. Acta Trop 115: 14-21.
2. Young C, Losikoff P, Chawla A, Glasser L, Forman E, (2007) Transfusion-acquired Trypanosoma cruzi infection. Transfusion 47: 540-544.
3. Munoz J, Portus M, Corachan M, Fumado V, Gascon J, (2007) Congenital Trypanosoma cruzi infection in a non-endemic area. Trans R Soc Trop Med Hyg 101: 1161-1162.
4. Machado FS, Dutra WO, Esper L, Gollob KJ, Teixeira MM, et al. (2012) Current understanding of immunity to Trypanosoma cruzi infection and pathogenesis of Chagas disease. Semin Immunopathol. Ahead of print.
5. Rassi A Jr, Rassi A, Marin-Neto JA, (2011) Chagas disease. Lancet 375: 1388-1402.
6. Nagajyothi F, Machado FS, Burleigh BA, Jelicks LA, Scherer PE, et al. (2012) Mechanisms of Trypanosoma cruzi persistence in Chagas disease. Cell Microbiol 14: 634-643.
7. Bhatia V, Sinha M, Luxon B, Garg N, (2004) Utility of Trypanosoma cruzi sequence database for the identification of potential vaccine candidates: In silico and in vitro screening. Infect Immun 72: 6245-6254.
8. Vazquez-Chagoyan JC, Gupta S, Garg NJ, (2011) Vaccine development against Trypanosoma cruzi and Chagas disease. Adv Parasitol 75: 121-146.
9. Gupta S, Garg NJ, (2010) Prophylactic efficacy of TcVac2 against Trypanosoma cruzi in mice. PLoS Negl Trop Dis 4: e797.
10. Bhatia V, Garg NJ, (2008) Previously unrecognized vaccine candidates control Trypanosoma cruzi infection and immunopathology in mice. Clin Vaccine Immunol 15: 1158-1164.
11. Aparicio-Burgos JE, Ochoa-Garcia L, Zepeda-Escobar JA, Gupta S, Dhiman M, et al. (2011) Testing the efficacy of a multi-component DNA-prime/DNA-boost vaccine against Trypanosoma cruzi infection in dogs. PLoS Negl Trop Dis 5: e1050.
12. Gupta S, Garg NJ, (2012) Delivery of antigenic candidates by a DNA/MVA heterologous approach elicits effector CD8(+)T cell mediated immunity against Trypanosoma cruzi. Vaccine, Ahead of print.
13. Dhiman M, Estrada-Franco JG, Pando JM, Ramirez-Aguilar FJ, Spratt H, et al. (2009) Increased myeloperoxidase activity and protein nitration are indicators of inflammation in patients with Chagas' disease. Clin Vaccine Immunol 16: 660-666.
14. Barrio A, Mora MC, Ramos F, Moreno S, Samson R, et al. (2007) Use of kDNA-based polymerase chain reaction as a sensitive and differentially diagnostic method of American tegumentary leishmaniasis in disease-endemic areas of northern Argentina. Am J Trop Med Hyg 77: 636-639.
15. Marco JD, Barroso PA, Mimori T, Locatelli FM, Tomatani A, et al. (2012) Polymorphism-specific PCR enhances the diagnostic performance of American tegumentary leishmaniasis and allows the rapid identification of Leishmania species from Argentina. BMC Infect Dis 12: 191.
16. del Puerto R, Nishizawa JE, Kikuchi M, Iihoshi N, Roca Y, et al. (2010) Lineage analysis of circulating Trypanosoma cruzi parasites and their association with clinical forms of Chagas disease in Bolivia. PLoS Negl Trop Dis 4: e687.
17. Diez C, Lorenz V, Ortiz S, Gonzalez V, Racca A, et al. (2010) Genotyping of Trypanosoma cruzi sublineage in human samples from a North-East Argentina area by hybridization with DNA probes and specific polymerase chain reaction (PCR). Am J Trop Med Hyg 82: 67-73.
18. Montamat EE, De Luca D'Oro GM, Gallerano RH, Sosa R, Blanco A, (1996) Characterization of Trypanosoma cruzi populations by zymodemes: correlation with clinical picture. Am J Trop Med Hyg 55: 625-628.
19. Ruiz-Sanchez R, Leon MP, Matta V, Reyes PA, Lopez R, et al. (2005) Trypanosoma cruzi isolates from Mexican and Guatemalan acute and chronic chagasic cardiopathy patients belong to Trypanosoma cruzi I. Mem Inst Oswaldo Cruz 100: 281-283.
20. Bosseno MF, Barnabe C, Magallon Gastelum E, Lozano Kasten F, Ramsey J, et al. (2002) Predominance of Trypanosoma cruzi lineage I in Mexico. J Clin Microbiol 40: 627-632.
21. Tobler LH, Contestable P, Pitina L, Groth H, Shaffer S, et al. (2007) Evaluation of a new enzyme-linked immunosorbent assay for detection of Chagas antibody in US blood donors. Transfusion 47: 90-96.
22. World Health Organization (2008) International meeting: new diagnostic tests are urgently needed to treat patients with Chagas disease. Rev Soc Bras Med Trop 41: 315-319.
23. Ribeiro AL, Rocha MO, (1998) Indeterminate form of Chagas disease: considerations about diagnosis and prognosis. Rev Soc Bras Med Trop 31: 301-314.
24. World Health Organization (2010) Chagas disease control and elimination. Report of the secretariat. WHO, Geneva, UNDP/World Bank/WHO, http://appswhoint/gb/ebwha/pdf_files/WHA63/A63_17-enpdf.
25. Gomes YM, Lorena VM, Luquetti AO, (2009) Diagnosis of Chagas disease: what has been achieved? What remains to be done with regard to diagnosis and follow up studies? Mem Inst Oswaldo Cruz 104 Suppl 1: 115-121.
26. De Marchi CR, Di Noia JM, Frasch AC, Amato Neto V, Almeida IC, et al. (2011) Evaluation of a recombinant Trypanosoma cruzi mucin-like antigen for serodiagnosis of Chagas' disease. Clin Vaccine Immunol 18: 1850-1855.
27. Camussone C, Gonzalez V, Belluzo MS, Pujato N, Ribone ME, et al. (2009) Comparison of recombinant Trypanosoma cruzi peptide mixtures versus multiepitope chimeric proteins as sensitizing antigens for immunodiagnosis. Clin Vaccine Immunol 16: 899-905.
28. Umezawa ES, Luquetti AO, Levitus G, Ponce C, Ponce E, et al. (2004) Serodiagnosis of chronic and acute Chagas' disease with Trypanosoma cruzi recombinant proteins: results of a collaborative study in six Latin American countries. J Clin Microbiol 42: 449-452.
29. Araujo FG, (1986) Analysis of Trypanosoma cruzi antigens bound by specific antibodies and by antibodies to related trypanosomatids. Infect Immun 53: 179-185.
30. Camargo ME, Segura EL, Kagan IG, Souza JM, Carvalheiro Jda R, et al. (1986) Three years of collaboration on the standardization of Chagas' disease serodiagnosis in the Americas: an appraisal. Bull Pan Am Health Organ 20: 233-244.
31. Mendes RP, Hoshino-Shimizu S, Moura da Silva AM, Mota I, Heredia RA, et al. (1997) Serological diagnosis of Chagas' disease: a potential confirmatory assay using preserved protein antigens of Trypanosoma cruzi. J Clin Microbiol 35: 1829-1834.
32. Passos VM, Volpini AC, Braga EM, Lacerda PA, Ouaissi A, et al. (1997) Differential serodiagnosis of human infections caused by Trypanosoma cruzi and Leishmania spp. using ELISA with a recombinant antigen (rTc24). Mem Inst Oswaldo Cruz 92: 791-793.
33. Salles NA, Sabino EC, Cliquet MG, Eluf-Neto J, Mayer A, et al. (1996) Risk of exposure to Chagas' disease among seroreactive Brazilian blood donors. Transfusion 36: 969-973.
34. Krautz GM, Kissinger JC, Krettli AU, (2000) The targets of the lytic antibody response against Trypanosoma cruzi. Parasitol Today 16: 31-34.
35. Antas PR, Medrano-Mercado N, Torrico F, Ugarte-Fernandez R, Gomez F, et al. (1999) Early, intermediate, and late acute stages in Chagas' disease: a study combining anti-galactose IgG, specific serodiagnosis, and polymerase chain reaction analysis. Am J Trop Med Hyg 61: 308-314.
36. Cordeiro FD, Martins-Filho OA, Da Costa Rocha MO, Adad SJ, Correa-Oliveira R, et al. (2001) Anti-Trypanosoma cruzi immunoglobulin G1 can be a useful tool for diagnosis and prognosis of human Chagas' disease. Clin Diagn Lab Immunol 8: 112-118.
37. Galvao LM, Nunes RM, Cancado JR, Brener Z, Krettli AU, (1993) Lytic antibody titre as a means of assessing cure after treatment of Chagas disease: a 10 years follow-up study. Trans R Soc Trop Med Hyg 87: 220-223.